It also provides Pharmaceutical compositions comprising these compounds and processes for using the compounds for treating diseases or conditions mediated by the Spleen Tyrosine Kinase (SYK).Claim 1: a compound of formula (1) or one of its pharmaceutically acceptable salts, in which: R1 is selected from the group consisting of: (i) c1-3 alkyl； (ii) fluoroalquilo； (iii) - ch2or1a A1A, which is selected from the group consisting of H and alkyl C1 - 6； (iv) - N (r1b) 2In which each occurrence of r1b is selected from the group consisting of H, alkyl or two r1b 3 C1 - together with the N Atom are United to form a group of formula (2), in which R is 1, 2, 3 or 4； (V) - or - (alkyl C1 3)； (vi) - N (H) C (o) - (alkyl c1-3)； (vii) Halo； (viii) and (IX) (H； ILO； R2 is - O - O - (c1-3 alkyl) - N (2, 2a)N (2a) - C (o) - R2B or - F； in the 2a is selected from the group consisting of H, alkyl c1-3 alkyl； and R2B is C1 - 6； R3 is co2r3a ch2co2r3a -, -, - ch2ch2co2r3a, tetrazol, - C (o) n (r3b) 2 - CH2OH, h, alkyl, Halo, C1 - 6 - Oh -, - or - (c1-3 alkyl) - N (r3b) 2, - CN, - C (o) n (H) s (OR) 2r3c, - C (o) - N (H) (R3D), - C (o) N (H) or (C R3A,)- P (o) (or3b) 2 or - B (OH) 2； where R3A is selected from the group which consists of H and alkyl C1 - 6； where each r3b is selected independently from the group consisting of H, alkyl c1-3； where R3C is selected from the group consisting of alkyl C1 - 3 - 3 fluoroalquilo cycloalkyl, C1, C3 - 6 And phenylWhere the phenyl is replaced without replacing or with one or two c1-3 alkyl； where R3D is selected from the group consisting of - CN, - or - (alkyl c1-3) and tetrazol； R4 is co2r4a ch2co2r4a ch2ch2co2r4a tetrazol,, -,, - C (o) n (r4b) 2 - CH2OH, h, alkyl, Halo, C1 - Oh, - 6, - or - (c1-3 alkyl) - N (r4b) 2 CN C (o) n (H) s (OR) 2r4c, - C (o) - N (H) (R4D), C (o) n (H) C (o) R4A,- P (o) (or4b) 2 or - B (OH) 2； where R4A is selected from the group consisting of H, alkyl and C1 - 6； where each r4b is selected independently among the group
